-

Scipher Medicine Leadership to Present at the 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Alif Saleh, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:30 a.m. ET.

Conference participants can view the presentation through J.P. Morgan’s EventCenter.

About Scipher Medicine®

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, our proprietary network medicine platform, we commercialize tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, health care providers, and pharmaceutical companies to bring solutions to patients with autoimmune diseases. Visit http://www.sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

Contacts

Scipher Medicine:

Media Relations
Matt Burns
VP, Head of Communications
PR@scipher.com
518-423-5907

Investor Relations
John Strumbos, Ph.D., MBA
Chief Financial Officer
IR@scipher.com

Scipher Medicine


Release Summary
Scipher Medicine Chief Executive Officer Alif Saleh will present at the 40th Annual J.P. Morgan Healthcare Conference.
Release Versions

Contacts

Scipher Medicine:

Media Relations
Matt Burns
VP, Head of Communications
PR@scipher.com
518-423-5907

Investor Relations
John Strumbos, Ph.D., MBA
Chief Financial Officer
IR@scipher.com

More News From Scipher Medicine

Scipher Medicine and Maxymune Therapeutics Announce Strategic Collaboration to Accelerate Target Discovery in Autoimmune and Inflammatory Diseases

BURLINGTON, Mass.--(BUSINESS WIRE)--Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, today announced a strategic collaboration with Maxymune Therapeutics, a biotechnology company focused on research and development of novel therapeutics for immunological disorders. Through this partnership, Maxymune will leverage Scipher’s platform to capitalize on Scipher’s target ranking capabilities across research and development programs. Under the terms of the agreement, Sc...

Scipher Medicine Launches ClinicalTrialRank.com: A Breakthrough AI Platform to Predict Clinical Trial Failure and Revolutionize Drug Development Investment Strategy

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leader in precision immunology, today announced the public launch of ClinicalTrialRank.com, an innovative artificial intelligence (AI) platform engineered to predict clinical trial failure with unprecedented accuracy. This cutting-edge capability is poised to transform drug development, enabling biopharmaceutical companies and investors to make more informed decisions and avoid investing billions in therapies destined to fail. ClinicalTrialRa...

Scipher and Savant Bio Partner to Build the Most Comprehensive Clinico-Genomic Dataset in Rheumatoid Arthritis

NEW YORK & WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, today announced an expanded strategic partnership to build the world’s most advanced clinicogenomic dataset in rheumatoid arthritis (RA). The collaboration aims to generate high-resolution insights to support academic research, clinical trial design, therapeutic strategy, and real-world evidence generation. The collaboration centers...
Back to Newsroom